• SENSEX
    NIFTY 50
Business

​USFDA increases inspections of Indian drug facilities, investors remain concerned

Updated : January 20, 2020 02:47 PM IST

In what has been a tough start for Lupin, their Vizag API manufacturing plant was inspected by the USFDA and issued 5 observations. 
The street seems most concerned about Lupin because the regulatory developments in 2020 join a list of already outstanding issues for the company.
​USFDA increases inspections of Indian drug facilities, investors remain concerned

You May Also Like

Live TV
Advertisement